IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars

Benzinga_recent_news04-13 19:48

IDEAYA Biosciences Inc. (NASDAQ:IDYA) shares are up during Monday’s premarket session following the announcement of positive topline results from the Phase 2/3 trial for darovasertib in combination ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2627430977?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/13/Eye-In-Close-Up-With-Light-Blue-Iris-Det.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-04-13 19:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627430977","market":"hk","top_or_hot":-1,"title":"IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars","media":"Benzinga_recent_news","content":"<div>\n<p>IDEAYA Biosciences Inc. (NASDAQ:IDYA) shares are up during Monday’s premarket session following the announcement of positive topline results from the Phase 2/3 trial for darovasertib in combination ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/04/51775855/ideaya-eye-cancer-trial-data-beats-standard-therapy-stock-soars\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-13 19:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/04/51775855/ideaya-eye-cancer-trial-data-beats-standard-therapy-stock-soars><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>IDEAYA Biosciences Inc. (NASDAQ:IDYA) shares are up during Monday’s premarket session following the announcement of positive topline results from the Phase 2/3 trial for darovasertib in combination ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/04/51775855/ideaya-eye-cancer-trial-data-beats-standard-therapy-stock-soars\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IDYA","symbol_name":"IDEAYA Biosciences","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/04/51775855/ideaya-eye-cancer-trial-data-beats-standard-therapy-stock-soars","article_id":"2627430977","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/13/Eye-In-Close-Up-With-Light-Blue-Iris-Det.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/04/51775855/ideaya-eye-cancer-trial-data-beats-standard-therapy-stock-soars","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2627430977","pubTimestamp":1776080880,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"IDEAYA shares rise after darovasertib trial shows progression-free survival benefit in uveal melanoma; NDA filing planned for 2026.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IDYA":"IDEAYA Biosciences","BK4211":"区域性银行","SMP":"Standard Motor Products Inc","RSI":"Rush Street Interactive, Inc.","ORR":"Militia Long/Short Equity ETF","SMA":"Smartstop Self Storage REIT Inc","BK4124":"机动车零配件与设备","BK4150":"赌场与赌博","PFS":"Provident Financial Services Inc","BK4139":"生物科技","BK4195":"互助储蓄与抵押信贷金融服务","BK4217":"自存仓储房地产信托"},"translate_title":"IDEAYA眼癌试验数据击败标准疗法，股价飙升","themeId":"136b75c5fc6d3e3cb6dd1c794553aeae","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ORR":1,"IDYA":1,"SMP":1.5,"SMA":1,"PFS":1,"RSI":1},"content_text":"IDEAYA Biosciences Inc. (NASDAQ:IDYA) shares are up during Monday’s premarket session following the announcement of positive topline results from the Phase 2/3 trial for darovasertib in combination with crizotinib.\nThe news highlights the potential for a new treatment option for patients with metastatic uveal melanoma, a type of eye cancer.\nIDEAYA is a precision medicine oncology company focused on the discovery, development, and commercialization of cancer therapies.\nThe study showed a statistically significant improvement in median progression-free survival (PFS) for the darovasertib combination compared to the investigator’s choice of therapy (ICT).\nTrial met the primary endpoint, showing statistically significant improvement in median PFS, with 6.9 months for the darovasertib combination versus 3.1 months for ICT.\nPatients treated with the darovasertib combination reduced their risk of disease progression by 58%.\nThe secondary endpoints in the study include overall response rate (ORR) and duration of response (DOR). \nSecondary endpoint of overall response rate was 37.1% for the darovasertib combination versus 5.8% for ICT.\nThere were 5 complete responses observed in the darovasertib combination arm, and no complete responses observed in the ICT arm.\nThe median duration of response (DOR) in the darovasertib combination arm was 6.8 months.\nDarovasertib combination showed an early trend in improvement for overall survival versus ICT. It was well-tolerated, with a manageable safety profile.\nThe company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026 based on these results.\nAt $41.02, the stock is trading 27.7% above its 20-day simple moving average (SMA) and 21.8% above its 100-day SMA, suggesting strong short-term momentum. The stock is also 38.1% above its 200-day SMA, indicating a solid long-term uptrend.\nThe relative strength index (RSI) is currently at 41.52, which suggests a neutral momentum, indicating that the stock is neither overbought nor oversold.\nThe moving average convergence divergence (MACD) is bearish, with the MACD at -0.5310 and the signal line at -0.3888, suggesting that downward pressure may be present.\nThe stock has shown a remarkable 12-month performance of 78.26%, reflecting strong investor interest and positive sentiment over the past year.\nCurrently, it is trading near its 52-week high of $41.02, which suggests bullish sentiment among traders.\nIDYA Stock Price Activity: IDEAYA Biosciences shares were up 26.36% at $38.60 during premarket trading on Monday, according to Benzinga Pro data.\nImage via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2627430977","isCrawlerRequest":true}